RT @synovialjoints: Plenary: Remibrutinib (LOU064) a BTK inhibitor in Sjogrenâs ⦠Favourable safety profile ⦠Well
Tweet Content
Plenary:
Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s
◦ Favourable safety profile
◦ Well-tolerated over 24 Wks
◦ Improved ESSDAI, salivary flow, Igs
◦ May be first effective oral disease-modifying therapy for SS
Dorner T Abs1113 https://t.co/FkgJpwKAJL #ACR22 @RheumNow https://t.co/znxMc27EBI
Links
Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a…
http://bit.ly/3WZOXIH
Show on Archive Page
On
Display in Search Results
On
PDQ
Off